Use of a pMDI with a holding chamber is noninferior to nebulization for delivering salbutamol in children with asthma exacerbations.

Stepping down to as-needed ICS/FABA maintained asthma stability while significantly reducing steroid exposure in individuals ...

S hifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization, a ...

Background: Previous guidelines recommend doubling the daily dose of maintenance inhaled corticosteroid to treat or prevent progression of exacerbations of asthma. Methods: Over a 6 month period a ...

This review aimed to assess the safety and efficacy of intravenous aminophylline in addition to standard first-line treatment with inhaled/nebulised Short-Acting Beta Agonist (SABA) and systemic ...

Albuterol-budesonide (Airsupra; AstraZeneca) resulted in a 47% reduction in severe exacerbations in mild asthma vs albuterol alone.

Background We aimed to evaluate the efficacy and safety of single combined fast-acting beta2-agonist/inhaled corticosteroid (FABA/ICS) inhaler only used as needed in people with mild asthma. Methods ...

Background Evidence regarding high-dose inhaled corticosteroids (HDICS) in asthma exacerbations in adults is insufficient. This study compares the treatment outcomes of HDICS as add-on therapy to the ...

There may be a more effective treatment for severe asthma and chronic obstructive pulmonary disease (COPD) attacks than that used as the standard of care for 50 years, according to a recent study.

Stepping-up to a maximal dose of inhaled corticosteroids (ICS) following a severe asthma exacerbation was not beneficial for preventing future exacerbations, according to research presented at the ...

Additionally, participants received standard-of-care treatment with medium- to high-dose inhaled corticosteroids plus at least one additional controller. The primary endpoint was reduction in the ...